2. Highlights | Corporate
2
The only Brazil’s mixed market player that features exposure and expansion capacity
in the segments of Retail, Hospital & Specialties and Distribution;
Strategic partnership with AmerisourceBergen, the world’s largest player in the
pharmaceutical specialties, resulting in the creation of the company Profarma
Specialty;
The Company carried out four acquisitions over the last three years, including its
entry into the Retail pharmaceutical segment, and the attainment of a market position
as one of the major players within this segment in the state of Rio de Janeiro;
Proven capacity to integrate acquisitions, combining all group companies in the SAP
plataform.
3. Highlights | 1Q15
3
CONSOLIDATED
(considering 100% of all companies)
• Consolidated EBITDA rose by 30.6% to R$ 19.7 million in
1Q15, with EBITDA margin of 2.0%;
• Operating expenses fell by 1.6 p.p. year-over-year in 1Q15;
• Gross revenues climbed by 11.0% from 1Q14;
• The annual price increase, on March 31, came to 5.5% on
average, the highest in the last six years and about 60%
higher than 1Q14 increase.
RETAIL
• Drogasmil’s and Tamoio’s sales rose respectively by 17.8%
and 8.2% year-over-year in 1Q15;
• Drogasmil’s EBITDA moved up by 28.3% and Tamoio’s by
10.2% in relation to 1Q14;
• Average monthly sales per store climbed by 15.6% at
Drogasmil and 8.2% at Tamoio against 1Q14;
• Drogasmil’s same stores sales (SSS) increased by 18.6%
and Tamoio’s by 8.2% in relation to 1Q14.
SPECIALTIES
• The division’s sales grew by 13.6%, with a year-over-year
increase of 18.2% in specialty wholesaling;
• Sales to the private sector climbed by 25.4% against 1Q14;
• Oncologicals sales increased by 62.3% in relation to 1Q14.
PHARMACEUTICAL DISTRIBUTION
• Sales increased by 6.6% against 1Q14;
• EBITDA moved up by 19.4% in relation to 1Q14 and EBITDA
margin stood at 2.0%;
• The independent customers segment grew by 9.3% vs.
1Q14;
• Sales of the branded category rose by 9.9% year-over-year
in 1Q15.
6. 6
Sales increased by 6.6% against
1Q14.
The division’s sales grew by 13.6%,
with a year-over-year increase of
18.2% in specialty wholesaling.
Drogasmil’s and Tamoio’s sales rose
respectively by 17.8% and 8.2% year-
over-year in 1Q15.
1Q14
976.6
4Q14
1,000.9
1Q15
943.5-3.1%
11.0%
54.6
1,031.2
181.1
1,182.0
201.3
1,144.8
Consolidated Performance
Gross Revenues Evolution
(R$ million)
Pharmaceutical Distribution
Specialties
Retail
Accounting Consolidated Gross Revenues
Pro-forma Consolidated Gross Revenues: 100% of revenues from
Tamoio, Drogasmil / Farmalife and Profarma Specialty
15. 2.0
1Q14 1Q15
1.8
7.9
1Q14 1Q15
7.9
10.3
1Q14 1Q15
10.1
873.0
1Q14 1Q15
818.7
Sales of the branded
category rose by 9.9% year-
over-year in 1Q15
The independent customers
segment grew by 9.3% vs.
1Q14;
EBITDA moved up by 19.4%
in relation to 1Q14 and
EBITDA margin stood at
2.0%;
15
Financial Data
(R$ million and % Net Revenues)
EBITDA Margin
(%)
Op. Exp. SG&A
(%)
Gross Margin
(%)
Gross Revenues
(R$ million)
Pharmaceutical Distribution
17. 17
1.6
1Q14 1Q15
1.6
9.8
1Q14 1Q15
11.3
11.8
1Q14 1Q15
13.4
166.3
1Q14 1Q15
146.3
The division’s sales grew by
13.6%, with a year-over-year
increase of 18.2% in
specialty wholesaling;
Oncologicals sales
increased by 62.3% in
relation to 1Q14.
Specialties
Financial Data
(R$ million and % Net Revenues)
EBITDA Margin
(%)
Op. Exp. SG&A
(%)
Gross Margin
(%)
Gross Revenues
(R$ million)
Sales to the private sector
climbed by 25.4% against
1Q14;
19. 19
5.2
1Q14 1Q15
5.1
23.4
1Q14 1Q15
25.9
28.8
1Q14 1Q15
31.1
102.3
1Q14 1Q15
94.6
Tamoio chain’s sales up
8.2% year-over-year;
Average monthly sales per
store up 8.2%, from R$ 525.5
thousand in 1Q14 to R$
568.4 thousand in 1Q15;
10.2% increase in EBITDA
vs. 1Q14;
Retail | Tamoio
Financial Data
(R$ million and % Net Revenues)
EBITDA Margin
(%)
Op. Exp. SG&A
(%)
Gross Margin
(%)
Gross Revenues
(R$ million)
Operating expenses down
2.5 p.p. in relation to 1Q14;
21. 21
0 Opening
0 Close-downs
0 Reformulated
50 Mature
1Q14
vs.
1Q15
1Q14
26.1
1Q15
28.8
4Q14
28.0
10.3%
2.7%
1Q14
60
4Q14
60
1Q15
60
0.0%
0.0%
Retail | Tamoio
# of Stores
(units)
Average Ticket
(in reais)
22. 22
-4.8
1Q14 1Q15
-7.8
32.5
1Q14 1Q15
38.1
30.6
1Q14 1Q15
29.3
72.0
1Q14 1Q15
61.2
Average monthly sales per
store up 15.6%, from R$
325.7 thousand in 1Q14 to
R$ 376.5 thousand in 1Q15;
Operating loss down 28.3%,
from R$ (4.8) million in 1Q14
to R$ (3.4) million in 1Q15.
Total gross margin up 1.3
p.p. when compared with
1Q14, totaling 30.6% in
1Q15;
Retail | Drogasmil/Farmalife
Financial Data
(R$ million and % Net Revenues)
EBITDA Margin
(%)
Op. Exp. SG&A
(%)
Gross Margin
(%)
Gross Revenues
(R$ million)
